Clinical Trial Update: Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated tandutinib in combination with bevacizumab for recurrent brain tumors, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Mixed Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tandutinib (tandutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2012-08-31